title: Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
abstract: BACKGROUND
  Evaluating the long term benefit of therapy in multiple sclerosis (MS) is challenging. Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established.
  
  
  METHODS
  In a patient cohort from the pivotal interferon β-1b trial, the value of clinical and MRI measures were analysed, both at baseline and during the RCT, for predicting long term physical and cognitive outcome.
  
  
  RESULTS
  Baseline disability correlated with both physical (R(2)=0.22; p<0.0001) and cognitive (R(2)=0.12; p<0.0001) outcome after 16 years. Accrual of disability during the RCT (R(2)=0.12; p<0.0001) and annualised relapse rates during the trial correlated with physical outcome (R(2)=0.12; p<0.0001) but not with cognition. In contrast, baseline MRI measures of atrophy and lesion burden correlated with cognitive (R(2)=0.21; p<0.0001), but not with physical, outcome. Accumulation of plaque burden measured by MRI did not correlate with late physical disability or with cognitive outcome. Multivariate regression analysis using stepwise elimination demonstrated that baseline variables contributed independently to predicting long term outcomes while trial outcome variables contributed little. Overall, and considerably dependent on baseline measures, the models developed by this method accounted for approximately half of the variance in long term cognitive and disability outcome.
  
  
  CONCLUSIONS
  Although on-trial change in some short term clinical measures correlated with long term physical and disability outcomes, the proportion of the variance explained by single commonly employed on-study variables was often small or undetectable. Better correlations were observed for several baseline measures, suggesting that long term outcome in MS may be largely determined early in the disease course. Trial registration number http://Clinical Trials.gov, study registration NCT00206635.
authors.affiliation: University of California, San Francisco, San Francisco, CA 94143-0114, USA. douglas.goodin@ucsf.edu
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Goodin
authors.forename: Anthony
authors.initials: A
authors.lastname: Traboulsee
authors.forename: Volker
authors.initials: V
authors.lastname: Knappertz
authors.forename: Anthony T
authors.initials: AT
authors.lastname: Reder
authors.forename: David
authors.initials: D
authors.lastname: Li
authors.forename: Dawn
authors.initials: D
authors.lastname: Langdon
authors.forename: Christian
authors.initials: C
authors.lastname: Wolf
authors.forename: Karola
authors.initials: K
authors.lastname: Beckmann
authors.forename: Andreas
authors.initials: A
authors.lastname: Konieczny
authors.forename: George C
authors.initials: GC
authors.lastname: Ebers
mesh_terms: D000328:Adult; D003071:Cognition; D006233:Persons with Disabilities / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D009483:Neuropsychological Tests; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000068576:Interferon beta-1b; D016899:Interferon-beta